Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1
Posted inClinical Updates Hematology-Oncology news Specialties

Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1

CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a favorable safety profile.
Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review
Posted inClinical Updates news Oncology Specialties

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and treatment duration implications.
Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide
Posted inClinical Updates Hematology-Oncology news Specialties Transplantation

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for underrepresented patient groups.
Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial
Posted inClinical Updates Oncology Specialties

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting safety concerns that preclude further development.
EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation
Posted inClinical Updates news OB/GYN & Women's Health Oncology

EPIK-O Trial Explores Alpelisib plus Olaparib Versus Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian Cancer Without BRCA Mutation

The phase III EPIK-O trial showed no progression-free survival benefit of alpelisib plus olaparib over chemotherapy in BRCA wild-type platinum-resistant or refractory high-grade serous ovarian cancer, highlighting treatment challenges and biomarker insights.